25.14
Inkretinmimetika (GLP-1-Rezeptoragonisten)
Zu den Inkretinen gehören das Glucagon-like Peptid-1 (GLP-1) und das glukoseabhängige insulinotrope Polypeptid (GIP), die die Insulinsekretion nach de…
Die orale Glukoseaufnahme löst Darmhormone wie GLP-1 und GIP aus, die Inkretine genannt werden und die Insulinsekretion stimulieren.
Sowohl GLPs als auch Glucagon stammen aus dem Präproglucagon. Proglucagon wird von intestinalen L-Zellen und spezifischen Neuronen des Hinterhirns zu einem großen Peptid verarbeitet, das Glucagon oder GLP-1 und GLP-2 enthält.
GLP-1 wird jedoch durch DPP-4 und Endopeptidasen abgebaut und renal ausgeschieden, was es therapeutisch ungeeignet macht.
Um dies zu umgehen, wurden metabolisch stabile GLP-1-Analoga entwickelt, darunter Dulaglutid, Liraglutid und Lixisenatid.
Diese Medikamente tragen dazu bei, die Blutzuckerkontrolle bei Typ-2-Diabetes-Patienten zu verbessern, entweder allein oder in Kombination mit anderen Medikamenten. Darüber hinaus führen sie zu einer Gewichtsabnahme und werden täglich oder wöchentlich in einer Form mit verlängerter Freisetzung verabreicht.
Exenatid ist eine synthetische Exendin-4-Peptidvariante. Es ist ein Analogon von GLP-1, wird aber von DPP-4 nicht metabolisiert, wodurch seine Wirkung verlängert wird.
Ein anderer Ansatz besteht darin, die DPP-4-Inhibitoren zu verwenden, die die therapeutische Wirksamkeit der Inkretine maximieren.
View the full transcript and gain access to JoVE Core videos
Q1: What are incretins and how do they affect insulin secretion?
Incretins are gut hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) released after oral glucose intake. They stimulate insulin secretion and are responsible for 50-70% of the postprandial insulin response. Both originate from preproglucagon and preproGIP respectively, processed by intestinal L cells and hindbrain neurons to regulate glucose homeostasis.
Q2: Why is native GLP-1 unsuitable as a therapeutic drug?
Native GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) and endopeptidases, then excreted renally, resulting in a short half-life of only 1-2 minutes. This rapid inactivation prevents therapeutic efficacy when administered systemically, necessitating alternative drug strategies to exploit GLP-1's beneficial effects on glucose control.
Q3: How do GLP-1 receptor agonists like liraglutide and dulaglutide work?
GLP-1 receptor agonists are metabolically stable analogs resistant to DPP-4 degradation and renal clearance. Drugs like liraglutide (Victoza) and dulaglutide (Trulicity) bind GLP-1 receptors to stimulate insulin secretion, inhibit glucagon release, slow gastric emptying, and reduce food intake. They improve glycemic control in type 2 diabetes and induce weight loss when administered daily or weekly.
Q4: What is exenatide and how does it differ from native GLP-1?
Exenatide (Byetta) is a synthetic exendin-4 peptide variant that shares physiological properties with GLP-1 but resists DPP-4 metabolism, extending its therapeutic action. Unlike native GLP-1, exenatide maintains effectiveness long enough for clinical use. It is administered alone or combined with other drugs to manage type 2 diabetes in patients failing to meet glycemic targets.
Q5: What are DPP-4 inhibitors and how do they enhance GLP-1 efficacy?
DPP-4 inhibitors are small-molecule drugs including sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus) that block the enzyme degrading GLP-1 and GIP. By preventing enzymatic inactivation, these inhibitors extend the action of endogenously released incretins, maximizing their therapeutic efficacy without requiring exogenous peptide administration.
Q6: What metabolic effects does GLP-1 therapy produce beyond glucose control?
GLP-1 therapy suppresses glucagon secretion, delays gastric emptying, inhibits feeding behavior, and reduces hunger sensation in type 2 diabetes patients. These effects contribute to weight loss and improved metabolic outcomes. The exact mechanism underlying reduced hunger remains unclear, but GLP-1 receptor activation in the hypothalamus and other brain regions likely plays a role.
Q7: How are GLP-1 agonists administered and what are their clinical advantages?
GLP-1 agonists are administered as daily or weekly extended-release injections, improving patient compliance compared to multiple daily doses. They effectively lower blood glucose, induce weight loss, and can be used alone or combined with other diabetes medications. Their flexible dosing regimens and dual metabolic benefits make them valuable options for managing type 2 diabetes.